Trovagene Grants Genoptix License for NPM1, ACADIA Gets Funding: Healthcare Business Recap
On Thursday, Trovagene (TROV) said that it has granted Genoptix (NYSE:NVS) a worldwide, non-exclusive license through which to incorporate nucleophosmin protein, NPM1, into research and clinical testing services for acute myelogenous leukemia. Presently, Trovagene holds an exclusive global license to United States patent 8,222,370 and the corresponding group of American and foreign patent applications around NPM1. Terms of the accord include upfront fees and royalty payments, but the financial terms were not disclosed.
The Medicines Company (NASDAQ:MDCO) reports that a late-stage trial of its experimental drug oritavancin met the main study target of stopping skin infection from spreading with the absence of fever. The drug is being evaluated for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Its trial, Solo-1, indicated that oritavancin was non-inferior to the standard-of-care antibiotic vancomycin in its efficacy.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
ACADIA Pharmaceuticals (NASDAQ:ACAD) said on Thursday that it will receive funding from Fast Forward, a not-for-profit organization set up by the National Multiple Sclerosis Society, and EMD Serono, which will support ACADIA research to be conducted in connetion with Dr. Rhonda Voskuhl of UCLA. ACADIA is a biopharmaceutical firm that is focused on innovative treatments which address unmet medical needs in neurological and related central nervous system disorders.
Mylan (NASDAQ:MYL) announced Thursday that it is recalling three lots of hydrocone bitartrate, the generic name for Vicodin, and acetaminophen tablets because a small number of tablets might have been too large and thus overly strong. The drugs were manufactured for Mylan by Qualitest, a division of Endo Health Solutions, which recalled 101 lots of the pills earlier in December for the same reason. This recall concerns only pills labeled with 10 milligrams of hydrocodone bitartrate and 500 milligrams of acetaminophen, the generic ingredient in Tylenol.
Investing Insights: Is Mondelez International a Safe Bet in an Unstable Economy?